23 results on '"von dem Borne, Peter A."'
Search Results
2. Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome.
- Author
-
van Grootveld, Rebecca, Masarotto, Valentina, von dem Borne, Peter A., Blijlevens, Nicole M. A., Chitu, Dana A., van der Beek, Martha T., Fiocco, Marta, and de Boer, Mark G. J.
- Subjects
- *
ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *OLDER patients , *CAUSES of death , *ASPERGILLOSIS , *PULMONARY aspergillosis - Abstract
Purpose: Study objectives were to estimate the cumulative incidence of death due to different causes of death (CODs) and investigate the effect of invasive aspergillosis (IA) on each separate COD in a cohort of older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) included in the Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) 43 randomized controlled trial. Methods: Pre-collected data from the trial was obtained from the HOVON data center and relevant clinical information was extracted. The cumulative incidence of death due to different CODs was estimated with a competing risk model and the association between each COD and prognostic factors, including IA, were investigated with a cause-specific hazard Cox regression model. Results: In total 806 patients were included, mean age of 70 years and 55% were male. The cumulative incidences of death due to leukaemia or infection at 3, 6, 12 and 36 months were 0.06, 0.11, 0.23, 0.42 and 0.17, 0.19, 0.22, 0.25 respectively. Incidence of IA was 21% and diagnosis of IA up until the final chemotherapy cycle was associated with an increased risk of dying from leukaemia (cause-specific hazard ratio (CSHR): 1.75, 95% CI 1.34–2.28) and a trend was seen for infection (CSHR: 1.36, 95% CI 0.96–1.91). Conclusion: Leukaemia was the most likely cause of death over time, however in the first year after diagnosis of AML or high-risk MDS infection was the most likely cause of death. Patients with IA had a relatively increased risk of dying from leukaemia or infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
- Author
-
Baron, Frédéric, Nagler, Arnon, Galimard, Jacques‐Emmanuel, Sanz, Jaime, Versluis, Jurjen, Forcade, Edouard, Chevallier, Patrice, Sirvent, Anne, Anthias, Chloe, Kuball, Jürgen, Furst, Sabine, Rambaldi, Alessandro, Sierra, Jorge, von dem Borne, Peter A., Gallego Hernanz, Maria Pilar, Cluzeau, Thomas, Robinson, Stephen, Raiola, Anna Maria, Labussière‐Wallet, Hélène, and Byrne, Jenny L.
- Subjects
- *
CORD blood transplantation , *ACUTE myeloid leukemia , *ACUTE leukemia , *CELL transplantation - Abstract
Summary: We investigated whether secondary versus de novo acute myeloid leukaemia (AML) would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT). This is a retrospective study from the acute leukaemia working party of the European Society for Blood and Marrow Transplantation. Inclusion criteria included adult at first allogeneic haematopoietic cell transplantation between 2000 and 2021, unrelated single or double unit CBT, AML in CR1, no ex vivo T‐cell depletion and no post‐transplant cyclophosphamide. The primary end‐point of the study was leukaemia‐free survival (LFS). A total of 879 patients with de novo (n = 696) or secondary (n = 183) AML met the inclusion criteria. In multivariable analyses, sAML patients had non‐significantly different LFS (HR = 0.98, p = 0.86), overall survival (HR = 1.07, p = 0.58), relapse incidence (HR = 0.74, p = 0.09) and non‐relapse mortality (HR = 1.26, p = 0.13) than those with de novo AML. Our results demonstrate non‐significantly different LFS following CBT in adult patients with secondary versus de novo AML. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Clinical Impact of Polymerase Chain Reaction–Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study.
- Author
-
Huygens, Sammy, Dunbar, Albert, Buil, Jochem B, Klaassen, Corné H W, Verweij, Paul E, Dijk, Karin van, Jonge, Nick de, Janssen, Jeroen J W M, Velden, Walter J F M van der, Biemond, Bart J, Bart, Aldert, Bruns, Anke H W, Haas, Pieter-Jan A, Demandt, Astrid M P, Oudhuis, Guy, von dem Borne, Peter, Beek, Martha T van der, Klein, Saskia K, Godschalk, Peggy, and Span, Lambert F R
- Subjects
- *
RESEARCH , *GENETIC mutation , *CONFIDENCE intervals , *MANN Whitney U Test , *PULMONARY aspergillosis , *PEARSON correlation (Statistics) , *DESCRIPTIVE statistics , *CHI-squared test , *POLYMERASE chain reaction , *DRUG resistance in microorganisms , *BIOLOGICAL assay , *DATA analysis software , *COMPUTED tomography , *LONGITUDINAL method - Abstract
Background Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy. Methods In a prospective study, we evaluated the clinical value of the AsperGenius polymerase chain reaction (PCR) assay in hematology patients from 12 centers. This PCR assay detects the most frequent cyp51A mutations in A. fumigatus conferring azole resistance. Patients were included when a computed tomography scan showed a pulmonary infiltrate and bronchoalveolar fluid (BALf) sampling was performed. The primary end point was antifungal treatment failure in patients with azole-resistant IA. Results Of 323 patients enrolled, complete mycological and radiological information was available for 276 (94%), and probable IA was diagnosed in 99/276 (36%). Sufficient BALf for PCR testing was available for 293/323 (91%). Aspergillus DNA was detected in 116/293 (40%) and A. fumigatus DNA in 89/293 (30%). The resistance PCR was conclusive in 58/89 (65%) and resistance detected in 8/58 (14%). Two had a mixed azole-susceptible/azole-resistant infection. In the 6 remaining patients, treatment failure was observed in 1. Galactomannan positivity was associated with mortality (P =.004) while an isolated positive Aspergillus PCR was not (P =.83). Conclusions Real-time PCR-based resistance testing may help to limit the clinical impact of triazole resistance. In contrast, the clinical impact of an isolated positive Aspergillus PCR on BALf seems limited. The interpretation of the EORTC/MSGERC PCR criterion for BALf may need further specification (eg, minimum cycle threshold value and/or PCR positive on >1 BALf sample). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Rhinovirus viremia in adult patients with high viral load in bronchoalveolar lavages.
- Author
-
Van Rijn, Anneloes L., Claas, Eric C., von dem Borne, Peter A., Kroes, Aloys C.M., and de Vries, Jutte J.C.
- Subjects
- *
VIREMIA , *VIRAL load , *BRONCHOALVEOLAR lavage , *RHINOVIRUSES , *CHILDREN'S health - Abstract
Background In children, rhinovirus viremia has been associated with higher nasopharyngeal loads and increase in severity of clinical signs and symptoms. Objectives This study aims to detect rhinovirus viremia in adult patients and to establish potential correlations with the clinical course. Study design Adult patients with rhinovirus strongly positive bronchoalveolar lavages (BAL, quantitation cycle, Cq values <25) detected between 2008 and 2014 were studied retrospectively. Blood sampled between two weeks before and two weeks after BAL sampling was tested for rhinovirus RNA. Underlying conditions, symptoms, radiography, microbiological data, and disease outcome were analysed. Results Twenty-seven of 43 patients with rhinovirus positive BAL at Cq values <25 had blood samples available within the prespecified time-frame (mean blood 3–4 samples per patient). Four of these 27 patients (15%) tested rhinovirus RNA positive in their blood (of whom one patient twice). Genotyping demonstrated rhinovirus A01, A24, B52 and B92 in these four immunocompromised patients. Viremic patients were not significantly different with regard to underlying conditions, respiratory symptoms, radiological findings, co-pathogens nor the number of blood samples tested for RV. However, patients with rhinovirus viremia had significant higher mortality rates compared to patients without viremia, as all four died as a consequence of respiratory problems (100%) versus 22% (5/23), p = 0.007 (Fisher’s exact). Conclusions Rhinovirus viremia can occur in adult patients with a high viral load in BAL fluid. Rhinovirus viremia may be considered a negative prognostic factor, although a causative role with regard to the adverse outcome has yet to be demonstrated. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia.
- Author
-
Cornelissen, Loes L., Kreuger, Aukje L., Caram‐Deelder, Camila, Huisman, Menno V., Middelburg, Rutger A., Kerkhoffs, Jean Louis H., von dem Borne, Peter A., Beckers, Erik A. M., de Vooght, Karen M. K., Kuball, Jürgen, van der Bom, Johanna G., and Zwaginga, Jaap Jan
- Subjects
- *
INTRACRANIAL hemorrhage , *CARDIOVASCULAR diseases risk factors , *ACUTE leukemia , *MYOCARDIAL ischemia , *CORONARY disease , *ENDOTHELIUM diseases - Abstract
Background: Intracranial hemorrhage is seen more frequently in acute leukemia patients compared to the general population. Besides leukemia‐related risk factors, also risk factors that are present in the general population might contribute to hemorrhagic complications in leukemia patients. Of those, cardiovascular risk factors leading to chronic vascular damage could modulate the occurrence of intracranial hemorrhage in these patients, as during their disease and treatment acute endothelial damage occurs due to factors like thrombocytopenia and inflammation. Objectives: Our aim was to explore if cardiovascular risk factors can predict intracranial hemorrhage in acute leukemia patients. Methods: In a case‐control study nested in a cohort of acute leukemia patients, including 17 cases with intracranial hemorrhage and 55 matched control patients without intracranial hemorrhage, data on cardiovascular risk factors were collected for all patients. Analyses were performed via conditional logistic regression. Results: Pre‐existing hypertension and ischemic heart disease in the medical history were associated with intracranial hemorrhage, with an incidence rate ratio of 12.9 (95% confidence interval [CI] 1.5 to 109.2) and 12.1 (95% CI 1.3 to110.7), respectively. Conclusion: Both pre‐existing hypertension and ischemic heart disease seem to be strong predictors of an increased risk for intracranial hemorrhage in leukemia patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Cucurbitacin I Inhibits Stat3 and Induces Apoptosis in Sézary Cells.
- Author
-
van Kester, Marloes S, Out-Luiting, Jacoba J, von dem Borne, Peter A, Willemze, Rein, Tensen, Cornelis P, and Vermeer, Maarten H
- Subjects
- *
LYMPH nodes , *SKIN diseases , *CYTOKINES , *WESTERN immunoblotting , *TUMORS - Abstract
Sézary syndrome (Sz) is an aggressive cutaneous CD4+ T-cell lymphoma with tumor cells (Sz cells) localized in the skin, lymph nodes, and peripheral blood. Using western blotting, we demonstrate the expression of phosphorylated (P)-Stat3 in the Sz-derived cell line Seax, and in freshly isolated tumor cells from Sz patients (n=6). In Vitro overnight culture without exogenous cytokines results in decreased expression of P-Stat3 (n=3), indicating that Stat3 is not constitutively activated. Incubation of the Seax cell line with the Jak/Stat3 inhibitor Cucurbitacin I resulted in a time- and concentration-dependent decrease of P-Stat3 and Stat3. In freshly isolated Sz cells (n=3), Cucurbitacin I induced a concentration-dependent decrease in Stat3 expression whereas P-Stat3 was undetectable. Finally, incubation of freshly isolated Sz cells (n=4) with 30 μM Cucurbitacin I for 6 hours induced apoptosis in the large majority (73–91%) of tumor cells. These data strengthen the notion that activation of Stat3 plays an essential part in the malignant transformation of Sz and provide further rationale for the therapeutical targeting of Stat3 in Sz.Journal of Investigative Dermatology (2008) 128, 1691–1695; doi:10.1038/sj.jid.5701246; published online 17 January 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
8. Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
- Author
-
Van Elssen, Catharina, van Gorkom, Gwendolyn, Voorter, Christine, von dem Borne, Peter, Meijer, Ellen, Wieten, Lotte, and Bos, Gerard
- Subjects
- *
KILLER cells , *MULTIPLE myeloma , *KILLER cell receptors , *STEM cell transplantation , *CLINICAL trial registries - Abstract
Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a haploidentical stem cell transplantation (haploSCT) can reduce the risk of myeloma relapse, we performed a small prospective phase 2 study in which we transplanted poor-risk MM patients using a killer cell immunoglobulin-like receptor (KIR)-ligand mismatched haploidentical donor. Patients received bone marrow grafts after reduced-intensity conditioning, with post-transplantation cyclophosphamide (PTCY) graft-versus-host-disease (GVHD) prophylaxis. The primary endpoint was 1.5-year progression-free survival (PFS); stopping rules were installed in case interim results made a benefit of 50% PFS at 1.5 years unlikely. After inclusion of 12 patients, of which 9 were evaluable for the primary endpoint, all patients relapsed within a median time of 90 days. All except 1 patient showed engraftment, with a median time to neutrophil recovery of 18 (12–30) days. The study was prematurely terminated based on the predefined stopping rules after the inclusion of 12 patients. With this small study, we show that in chemo-resistant myeloma patients, NK cell KIR-mismatch is not superior to conventional alloSCT. This strategy, however, can serve as a platform for new treatment concepts. Clinical Trial Registry: NCT02519114 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study.
- Author
-
Cornelissen, Loes L., Kreuger, Aukje L., Caram-Deelder, Camila, Middelburg, Rutger A., Kerkhoffs, Jean Louis H., von dem Borne, Peter A., Beckers, Erik A. M., de Vooght, Karen M. K., Kuball, Jürgen, Zwaginga, J. J., and van der Bom, Johanna G.
- Subjects
- *
BLOOD platelet transfusion , *ACUTE leukemia , *CASE-control method , *HEMORRHAGE , *PLATELET count - Abstract
We designed a study to describe the incidence of intracranial hemorrhage according to severity and duration of thrombocytopenia and to quantify the associations of platelet transfusions with intracranial hemorrhage in patients with acute leukemia. In this case-control study nested in a cohort of 859 leukemia patients, cases (n = 17) were patients diagnosed with intracranial hemorrhage who were matched with control patients (n = 55). We documented platelet counts and transfusions for seven days before the intracranial hemorrhage in cases and in a "matched" week for control patients. Three measures of platelet count exposure were assessed in four potentially important time periods before hemorrhage. Among these leukemia patients, we observed the cumulative incidence of intracranial hemorrhage of 3.5%. Low platelet counts were, especially in the three to seven days preceding intracranial hemorrhage, associated with the incidence of intracranial hemorrhage, although with wide confidence intervals. Platelet transfusions during the week preceding the hemorrhage were associated with higher incidences of intracranial hemorrhage; rate ratios (95% confidence interval) for one or two platelet transfusions and for more than two transfusions compared with none were 4.04 (0.73 to 22.27) and 8.91 (1.53 to 51.73) respectively. Thus, among acute leukemia patients, the risk of intracranial hemorrhage was higher among patients with low platelet counts and after receiving more platelet transfusions. Especially, the latter is likely due to clinical factors leading to increased transfusion needs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.
- Author
-
Roex, Marthe C.J., Wijnands, Charissa, Veld, Sabrina A.J., van Egmond, Esther, Bogers, Lisette, Zwaginga, Jaap J., Netelenbos, Tanja, von dem Borne, Peter A., Veelken, Hendrik, Halkes, Constantijn J.M., Falkenburg, J.H. Frederik, and Jedema, Inge
- Subjects
- *
ALEMTUZUMAB , *STEM cell transplantation , *SUPPRESSOR cells , *T cells , *GRAFT versus host disease , *STEM cells , *GRANULOCYTES , *BUSULFAN - Abstract
To reduce the risk of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT), T-cell depletion (TCD) of grafts can be performed by the addition of alemtuzumab (ALT) "to the bag" (in vitro) before transplantation. In this prospective study, the authors analyzed the effect of in vitro incubation with 20 mg ALT on the composition of grafts prior to graft infusion. Furthermore, the authors assessed whether graft composition at the moment of infusion was predictive for T-cell reconstitution and development of GVHD early after TCD alloSCT. Sixty granulocyte colony-stimulating factor-mobilized stem cell grafts were obtained from ≥9/10 HLA-matched related and unrelated donors. The composition of the grafts was analyzed by flow cytometry before and after in vitro incubation with ALT. T-cell reconstitution and incidence of severe GVHD were monitored until 12 weeks after transplantation. In vitro incubation of grafts with 20 mg ALT resulted in an initial median depletion efficiency of T-cell receptor (TCR) α/β T cells of 96.7% (range, 63.5–99.8%), followed by subsequent depletion in vivo. Graft volumes and absolute leukocyte counts of grafts before the addition of ALT were not predictive for the efficiency of TCR α/β T-cell depletion. CD4pos T cells were depleted more efficiently than CD8pos T cells, and naive and regulatory T cells were depleted more efficiently than memory and effector T cells. This differential depletion of T-cell subsets was in line with their reported differential CD52 expression. In vitro depletion efficiencies and absolute numbers of (naive) TCR α/β T cells in the grafts after ALT incubation were not predictive for T-cell reconstitution or development of GVHD post- alloSCT. The addition of ALT to the bag is an easy, fast and generally applicable strategy to prevent GVHD in patients receiving alloSCT after myeloablative or non-myeloablative conditioning because of the efficient differential depletion of donor-derived lymphocytes and T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.
- Author
-
Resendiz-Sharpe, Agustin, Mercier, Toine, Lestrade, Pieter P A, Beek, Martha T van der, Borne, Peter A von dem, Cornelissen, Jan J, Kort, Elizabeth De, Rijnders, Bart J A, Schauwvlieghe, Alexander F A D, Verweij, Paul E, Maertens, Johan, Lagrou, Katrien, van der Beek, Martha T, von dem Borne, Peter A, and De Kort, Elizabeth
- Subjects
- *
PULMONARY aspergillosis , *ASPERGILLOSIS , *HEMATOLOGY , *ASPERGILLUS fumigatus , *MORTALITY , *DISEASE prevalence - Abstract
Background: Increasing resistance of Aspergillus fumigatus to triazoles in high-risk populations is a concern. Its impact on mortality is not well understood, but rates from 50% to 100% have been reported.Objectives: To determine the prevalence of voriconazole-resistant A. fumigatus invasive aspergillosis (IA) and its associated mortality in a large multicentre cohort of haematology patients with culture-positive IA.Methods: We performed a multicentre retrospective study, in which outcomes of culture-positive haematology patients with proven/probable IA were analysed. Patients were stratified based on the voriconazole susceptibility of their isolates (EUCAST broth microdilution test). Mycological and clinical data were compared, along with survival at 6 and 12 weeks.Results: We identified 129 A. fumigatus culture-positive proven or probable IA cases; 103 were voriconazole susceptible (79.8%) and 26 were voriconazole resistant (20.2%). All but one resistant case harboured environment-associated resistance mutations in the cyp51A gene: TR34/L98H (13 cases) and TR46/Y121F/T289A (12 cases). Triazole monotherapy was started in 75.0% (97/129) of patients. Mortality at 6 and 12 weeks was higher in voriconazole-resistant cases in all patients (42.3% versus 28.2%, P = 0.20; and 57.7% versus 36.9%, P = 0.064) and in non-ICU patients (36.4% versus 21.6%, P = 0.16; and 54.4% versus 30.7%; P = 0.035), compared with susceptible ones. ICU patient mortality at 6 and 12 weeks was very high regardless of triazole susceptibility (75.0% versus 66.7%, P = 0.99; and 75.0% versus 73.3%, P = 0.99).Conclusions: A very high prevalence of voriconazole resistance among culture-positive IA haematology patients was observed. The overall mortality at 12 weeks was significantly higher in non-ICU patients with voriconazole-resistant IA compared with voriconazole-susceptible IA. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole‐resistance. A nationwide survey and rationale for the DB‐MSG 002 study protocol.
- Author
-
Schauwvlieghe, Alexander F. A. D., De Jonge, Nick, Van Dijk, Karin, Verweij, Paul E., Brüggemann, Roger J., Biemond, Bart J., Bart, Aldert, Von Dem Borne, Peter A., Verbon, Annelies, Van Der Beek, Martha T., Demandt, Astrid M. P., Oudhuis, Guy J., Cornelissen, Jan J., Van Der Velden, Walter J. F. M., Span, Lambert F. R., Kampinga, Greetje A., Bruns, Anke H., Vonk, Alieke G., Haas, Pieter-jan A., and Doorduijn, Jeanette K.
- Subjects
- *
ASPERGILLOSIS diagnosis , *ASPERGILLOSIS treatment , *INTRODUCED fungi , *PHYSIOLOGICAL effects of azoles , *HEMATOLOGY - Abstract
Summary: Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). A survey was conducted in all Dutch academic haematology centres on their current diagnostic, prophylactic and therapeutic approach towards IFD in the context of azole‐resistance. In all 8 centres, a haematologist and microbiologist filled in the questionnaire that focused on different subgroups of haematology patients. Fungal prophylaxis during neutropaenia was directed against Candida and consisted of fluconazole and/or amphotericin B suspension. Mould‐active prophylaxis was given to acute myeloid leukaemia patients during chemotherapy in 2 of 8 centres. All centres used azole prophylaxis in a subset of patients with graft‐versus‐host disease. A uniform approach towards the diagnosis and treatment of IFD and in particular azole‐resistant Aspergillus fumigatus was lacking. In 2017, all centres agreed to implement a uniform diagnostic and treatment algorithm regarding invasive aspergillosis with a central role for comprehensive diagnostics and PCR‐based detection of azole‐resistance. This study (DB‐MSG 002) will re‐evaluate this algorithm when 280 patients have been treated. A heterogeneous approach towards antifungal prophylaxis, diagnosis and treatment was apparent in the Netherlands. Facing triazole‐resistance, consensus was reached on the implementation of a uniform diagnostic approach in all 8 centres. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab- Based T Cell-Depleted Allogeneic Stem Cell Transplantation.
- Author
-
Loeff, Floris C., Falkenburg, J. H. Frederik, Hageman, Lois, Huisman, Wesley, Veld, Sabrina A. J., van Egmond, H. M. Esther, van de Meent, Marian, von dem Borne, Peter A., Veelken, Hendrik, Halkes, Constantijn J. M., and Jedema, Inge
- Subjects
- *
GENE frequency , *GENETIC mutation , *T cells , *ALEMTUZUMAB , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *THERAPEUTICS , *IMMUNOLOGY , *PHYSIOLOGY - Abstract
Alemtuzumab (ALM) is used for T cell depletion in the context of allogeneic hematopoietic stem cell transplantation (alloSCT) to prevent acute graft-versus-host disease and graft rejection. Following ALM-based T cell-depleted alloSCT, relatively rapid recovery of circulating T cells has been described, including T cells that lack membrane expression of the GPI-anchored ALM target Ag CD52. We show, in a cohort of 89 human recipients of an ALM-based T cell-depleted alloSCT graft, that early lymphocyte reconstitution always coincided with the presence of large populations of T cells lacking CD52 membrane expression. In contrast, loss of CD52 expression was not overt within B cells or NK cells. We show that loss of CD52 expression from the T cell membrane resulted from loss of GPI anchor expression caused by a highly polyclonal mutational landscape in the PIGA gene. This polyclonal mutational landscape in the PIGA gene was also found in CD52- T cells present at a low frequency in peripheral blood of healthy donors. Finally, we demonstrate that the GPI-/CD52- T cell populations that arise after ALM-based T cell-depleted alloSCT contain functional T cells directed against multiple viral targets that can play an important role in immune protection early after ALM-based T cell-depleted transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Distribution and clinical determinants of time‐to‐positivity of blood cultures in patients with neutropenia.
- Author
-
Lambregts, Merel M. C., Warreman, Eva B., Visser, Leo G., de Boer, Mark G., Bernards, Alexandra T., Veelken, Hendrik, von dem Borne, Peter A., and Dekkers, Olaf M.
- Subjects
- *
NEUTROPENIA , *BLOOD microbiology , *EMPIRICAL medicine , *BACTEREMIA , *PATIENTS , *THERAPEUTICS - Abstract
Abstract: Objectives: Blood cultures (BCs) are essential in the evaluation of neutropenic fever. Modern BC systems have significantly reduced the time‐to‐positivity (TTP) of BC. This study explores the probability of bacteraemia when BCs have remained negative for different periods of time. Methods: All adult patients with neutropenia and bacteraemia were included (January 2012‐February 2016). Predictive clinical factors for short (≤16 hours) and long (>24 hours) TTP were determined. The residual probability of bacteraemia was estimated for the scenario of negative BC 24 hours after collection. Results: The cohort consisted of 154 patients, accounting for 190 episodes of bacteraemia. Median age of 61 years, 60.5% were male. In 123 (64.7%) episodes, BC yielded a single Gram‐positive micro‐organism and in 49 (25.8%) a Gram‐negative micro‐organism (median TTP 16.7, 14.5 hours respectively,
P < .01). TTP was ≤24 hours in 91.6% of episodes. Central line‐associated bacteraemia was associated with long TTP. The probability of bacteraemia if BC had remained negative for 24 hours was 1%‐3%. Conclusions: The expected TTP offers guidance in the management of patients with neutropenia and suspected bacteraemia. The knowledge of negative BC can support a change in working diagnosis, and impact clinical decisions as soon as 24 hours after BC collection. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
- Author
-
van Bergen, Cornelis A. M., van Luxemburg-Heijs, Simone A. P., de Wreede, Liesbeth C., Eefting, Matthijs, von dem Borne, Peter A., van Balen, Peter, Heemskerk, Mirjam H. M., Mulder, Arend, Claas, Fransiscus H. J., Navarrete, Marcelo A., Honders, Wilhelmina M., Rutten, Caroline E., Veelken, Hendrik, Jedema, Inge, Halkes, Constantijn J. M., Griffioen, Marieke, and Falkenburg, J. H. Frederik
- Subjects
- *
GRAFT versus host disease , *T cells , *LEUKEMIA , *STEM cell transplantation , *MINOR histocompatibility antigens , *PATIENTS - Abstract
Patients with leukemia who receive a T cell-depleted allogeneic stem cell graft followed by postponed donor lymphocyte infusion (DLI) can experience graft-versus-leukemia (GVL) reactivity, with a lower risk of graft-versus-host disease (GVHD). Here, we have investigated the magnitude, diversity, and specificity of alloreactive CD8 T cells in patients who developed GVL reactivity after DLI in the absence or presence of GVHD. We observed a lower magnitude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with selective GVL reactivity without GVHD. Furthermore, we demonstrated that MiHA-specific T cell clones from patients with selective GVL reactivity showed lower reactivity against nonhematopoietic cells, even when pretreated with inflammatory cytokines. Expression analysis of MiHA-encoding genes showed that similar types of antigens were recognized in both patient groups, but in patients who developed GVHD, T cell reactivity was skewed to target broadly expressed MiHAs. As an inflammatory environment can render nonhematopoietic cells susceptible to T cell recognition, prevention of such circumstances favors induction of selective GVL reactivity without development of GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients.
- Author
-
Ten Brink, Marloes H., Swen, Jesse J., Böhringer, Stefan, Wessels, Judith A.m., Van Der Straaten, Tahar, Marijt, Erik W.a., Von Dem Borne, Peter A., Zwaveling, Juliëtte, and Guchelaar, Henk-Jan
- Abstract
Busulfan is used in preparative regimens before stem cell transplantation. There is significant interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. Polymorphisms in genes encoding glutathione-S-transferases have been associated with busulfan PK but only explain a limited portion of the observed variability.The aim of this study is to identify additional genetic variants associated with busulfan PK by interrogating 1936 variants in 225 genes involved in drug absorption, distribution, metabolism, and excretion (ADME).In an exploratory cohort (n=65), patients who received busulfan were genotyped with the DMET array. Top SNPs and haplotypes associated with busulfan clearance were validated in an independent validation cohort (n=78).In the exploratory cohort, seven variants were identified to be associated with busulfan clearance (P<0.001). In the validation cohort, only GSTA5 (rs4715354 and rs7746993) remained significantly associated with busulfan clearance (P=0.025).This is the first study using an exploratory pharmacogenetic approach to explain the interindividual variability in busulfan PK. The role of glutathione-S-transferases was confirmed, but no additional genetic markers involved in drug ADME appear to be associated with busulfan PK. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Alloreactive Effector T Cells Require the Local Formation of a Proinflammatory Environment to Allow Crosstalk and High Avidity Interaction with Nonhematopoietic Tissues to Induce GVHD Reactivity
- Author
-
van der Zouwen, Boris, Kruisselbrink, Alwine B., Jordanova, Ekaterina S., Rutten, Caroline E., von dem Borne, Peter A., Falkenburg, J.H. Frederik, and Jedema, Inge
- Subjects
- *
T cells , *INFLAMMATION , *HEMATOPOIETIC growth factors , *GRAFT versus host disease , *FIBROBLASTS , *GENE expression , *LYMPHOMAS - Abstract
Based on clinical observations that donor T cells specific for minor histocompatibility antigens (MiHA) ubiquitously expressed on both hematopoietic and nonhematopoietic cells were detected in patients showing evident graft-versus-leukemia/lymphoma (GVL) reactivity with no or limited coinciding graft-versus-host disease (GVHD), we hypothesized that nonhematopoietic tissues may be relatively unsusceptible to the cytotoxic effect of MiHA-specific T cells under normal, noninflammatory conditions. To test this hypothesis, we investigated the reactivity of alloreactive T cells specific for ubiquitously expressed MiHA against skin-derived primary human fibroblasts. We demonstrated that this reactivity was not merely determined by their antigen-specificity, but was highly dependent on adhesion molecule expression. ICAM-1 expression on the fibroblasts upregulated under proinflammatory conditions and induced during cross-talk with the T cells was demonstrated to be a crucial factor facilitating formation of high avidity interactions with the T cells and subsequent efficient target cell destruction. Furthermore, we provide supporting evidence for the role of ICAM-1 in vivo by demonstrating that ICAM-1 expression on nonhematopoietic target cells was dependent on the presence of infiltrating activated T cells, as was illustrated by restricted ICAM-1 expression at the sites of T cell infiltration in skin biopsies of patients with acute GVHD (aGVHD), by the absence of ICAM-1 expression in the same biopsies in areas without T cell infiltration and by the absence of ICAM-1 expression in biopsies of patients without GVHD independent of the presence of infiltrating nonactivated T cells. In conclusion, under noninflammatory conditions, nonhematopoietic tissues are unsusceptible to the GVHD reactivity of alloreactive T cells due to their inability to establish high avidity interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival.
- Author
-
de Witte, Theo, Brand, Ronald, van Biezen, Anja, Mufti, Ghulam, Ruutu, Tapani, Finke, Jürgen, von dem Borne, Peter, Vitek, Antonin, Delforge, Michel, Alessandrino, Paolo, Harlahakis, Nicolas, Russell, Nigel, Martino, Roberto, Verdonck, Leo, Kröger, Nicholas, and Niederwieser, Dietger
- Subjects
- *
STEM cell transplantation , *HLA histocompatibility antigens , *APLASTIC anemia , *ANEMIA diagnosis , *CELLULAR therapy - Abstract
Allogeneic stem cell transplantation (alloSCT) for patients with refractory anaemia may result in a 50% event-free survival, but the high non-relapse mortality (NRM) precludes a general application of this therapeutic modality. This study evaluated the impact of various pre-transplant variables, including disease duration, intensity of the conditioning regimen, type of donor and year of transplantation on outcome. The study population consisted of 374 patients; 244 were transplanted from human leucocyte antigen (HLA)-identical siblings and 130 patients from matched unrelated donors. The median age was 39 years. One hundred and two patients were transplanted after reduced intensity conditioning (RIC). The overall 4-year survival was 52%. The 4-year survival of patients transplanted with HLA-identical sibling donors and matched unrelated donors was 52% and 50%, respectively. Multivariate analysis showed an improved survival ( P = 0·05) and a lower NRM ( P = 0·02) when the transplantation was performed in recent years. Increasing age, and disease duration of >12 months were associated with inferior survival. RIC resulted in a similar survival despite an increased relapse risk ( P = 0·02). This improved outcome permits alloSCT in patients older than 50 years of age, even with the use of matched unrelated donors. AlloSCT should be preferentially performed early after diagnosis after careful analysis of prognostic variables. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
19. Identification of phosphatidylinositol 4-kinase type II β as HLA class II-restricted target in graft versus leukemia reactivity.
- Author
-
Griffioen, Marieke, van der Meijden, Edith D., Slager, Elisabeth H., Honders, M. Willy, Rutten, Caroline E., van Luxemburg-Heijs, Simone A. P., von dem Borne, Peter A., van Rood, Johannes J., Willemze, Roel, and Falkenburg, J. H. Frederik
- Subjects
- *
HEMATOLOGY , *PHOSPHOINOSITIDES , *FOCAL adhesion kinase , *LYMPHOCYTES ,LEUKEMIA genetics - Abstract
Patients with hematological malignancies can be successfully treated with HLA-matched T cell-depleted allogeneic stem cell transplantation (alloSCT) and subsequent donor lymphocyte infusions (DLIs). The efficacy of DLI is mediated by donor T cells recognizing minor histocompatibility antigens (mHags) on malignant recipient cells. Because HLA class II molecules are predominantly expressed on hematopoietic cells, mHag-specific CD4+ T cells may selectively mediate graft versus leukemia (GvL) reactivity without graft versus host disease (GvHD). In this study, we used a recombinant bacteria cDNA library for the identification of the first autosomal HLA class II (HLA-DQB1*0603)-restricted mHag LB-PI4K2B-1S encoded by the broadly expressed phosphatidylinositol 4-kinase type II β gene. A polyclonal CD4+ T cell response against LB-Pl4K2B-1S was demonstrated in a patient with relapsed chronic myeloid leukemia (CML) who responded to DLI after HLA-matched alloSCT. LB-PI4K2B-1S-specific CD4+ T cells recognized and lysed the CD344 CML cells of the patient and other leukemic cells as well as high HLA-DQ-expressing normal hematopoietic cells. HLA-DQ expression on normal cells of nonhematopoietic origin was moderately up-regulated by IFN-γ and not sufficient for T cell recognition. We hypothesize that LB-PI4K2B-1S-specific CD4+ T cells contributed to the antitumor response by both directly eliminating malignant cells as effector cells and stimulating CD8+ T cell immunity as helper cells. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
20. Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation
- Author
-
Hussein, Ayad Ahmed, Halkes, Constantijn M., Socié, Gérard, Tichelli, André, von dem Borne, Peter A., Schaap, Michel N.P.M., Foa, Robin, Ganser, Arnold, Dufour, Carlo, Bacigalupo, Andrea, Locasciulli, Anna, Aljurf, Mahmoud, Peters, Christina, Robin, Marie, van Biezen, Anja A., Volin, Liisa, De Witte, Theo, Marsh, Judith, Passweg, Jakob R., and Kröger, Nicolas
- Subjects
- *
MYELODYSPLASTIC syndromes , *HEMATOPOIETIC stem cell transplantation , *LEUKEMIA , *APLASTIC anemia , *SEVERITY of illness index , *BLOOD transfusion , *HEALTH outcome assessment - Abstract
One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
- Author
-
Loeff, Floris C., van Egmond, Esther H.M., Moes, Dirk J.A.R., Wijnands, Charissa, Von Dem Borne, Peter A., Veelken, Hendrik, Falkenburg, J.H. Frederik, Jedema, Inge, and Halkes, Constantijn J.M.
- Subjects
- *
STEM cell transplantation , *GRAFT versus host disease , *VIRUS diseases , *BLOOD volume , *ALEMTUZUMAB , *BK virus , *SEVERE combined immunodeficiency - Abstract
Administration of alemtuzumab (targeting the CD52 antigen) to the patient (in-vivo) or to the graft (in-vitro) before allogeneic stem cell transplantation (alloSCT) decreases the incidence of graft-versus-host disease (GvHD). Effectiveness of this treatment relies on depletion of donor T cells. Currently, no data are available on alemtuzumab pharmacokinetics and pharmacodynamics in patients who received combined in-vivo and in-vitro alemtuzumab-based T-cell depletion. In this prospective study, we analyzed alemtuzumab pharmacokinetics and its effect on the circulating T cells in 36 patients who received an allogeneic T-cell-depleted graft by addition of 20 mg alemtuzumab "to the bag" with or without prior alemtuzumab (30 mg cumulative dose intravenously) as part of the conditioning regimen. Effective T-cell depletion was shown for all patients, even though alemtuzumab plasma levels varied considerably. Peak alemtuzumab levels were observed directly after graft infusion and were not associated with the number of circulating T cells pre-infusion, but with plasma volumes of the patients. All patients engrafted, confirming feasibility of this transplantation protocol. Only three patients with low alemtuzumab levels developed acute GvHD (grade II in 2 patients and grade III in 1 patient). Persistence of circulating alemtuzumab at 3 weeks after transplantation had prevented reconstitution of CD52-positive T cells when alemtuzumab plasma levels were above 0.7 μg/mL. However, overall T-cell reconstitution did not correlate with the levels of alemtuzumab exposure, due to early reconstitution of CD52-negative alemtuzumab-resistant T cells. The protective effect of these cells likely explains the low incidence of Epstein-Barr-virus- and cytomegalovirus-related disease despite circulating alemtuzumab. • Peak alemtuzumab levels post-transplant correlated with patients' plasma volumes • Peak alemtuzumab levels above 6.5 μg/mL seemed protective against acute GvHD • Reconstitution of CD52-negative alemtuzumab-resistant T cells is frequently observed • Early reconstitution of CD52-negative T cells can contribute to anti-viral immunity [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. 90 - Identifying Permissible HLA-Mismatches in Unrelated-Donor Hematopoietic Stem-Cell Transplantation Using Predicted Indirectly Recognizable HLA Epitopes.
- Author
-
Thus, Kirsten A., Geneugelijk, Kirsten, van Deutekom, Hanneke, Calis, Jorg, Borst, Eric, Kesmir, Can, Oudshoorn, Machteld, van der Holt, Bronno, Meijer, Ellen, Zeerleder, Sacha, de Groot, Marco R., von dem Borne, Peter, Schaap, Nicolaas, Cornelissen, Jan, Kuball, Jurgen, and Spierings, Eric
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HLA histocompatibility antigens , *EPITOPES , *HEALTH outcome assessment , *DISEASE progression - Published
- 2017
- Full Text
- View/download PDF
23. Disseminated Cutaneous Mycobacterium chelonae Infection in a Patient With Acute Myeloid Leukemia.
- Author
-
Roukens, Anna Helena, Mendels, Elodie J., Verbeet, Nicolette L., von dem Borne, Peter A., Nicolae-Cristea, Alina R., Bentvelsen, Robbert G., van Doorn, Remco, and de Boer, Mark G.
- Subjects
- *
MYCOBACTERIUM , *MYCOBACTERIAL disease treatment , *PHYSIOLOGICAL effects of chemotherapy - Abstract
We report a case of disseminated cutaneous Mycobacterium chelonae infection in a patient who was treated with chemotherapy for acute myeloid leukemia. We discuss the clinical manifestations, diagnosis, and treatment of this unusual infection in neutropenic patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.